论文部分内容阅读
我院2003年以来共收治COPD急性加重并Ⅱ型呼吸衰竭患者44例,随机分为两组,治疗组23例,对照组21例,在积极抗感染、平喘、吸氧、扩血管、维持水电解质及酸碱平衡,激素应用等综合治疗基础上,治疗组用盐酸纳络酮0.8mg静注后2.4mg+5%GS 300m l静滴,每日1次,伴肺脑或缺氧严重者每日2次;对照组用尼可刹米0.75~1.5和洛贝林9~15mg+5%GS500m l静滴,每日1次,两组疗程均为5天,分别观察治疗后症状体征及24小时血气分析。结果,治疗组症状体征好转快,肺脑患者神志恢复时间短,24小时PH、PaO2明显上升,PaCO2明显下降,故认为纳络酮可作为一种新型的呼吸兴奋剂应用于临床。
A total of 44 patients with acute exacerbation of COPD and type Ⅱ respiratory failure have been treated in our hospital since 2003. They were randomly divided into two groups: 23 cases in the treatment group and 21 cases in the control group. They were active in anti-infection, antiasthmatic, oxygen-absorbing, vasodilator maintenance Water and electrolyte and acid-base balance, hormones and other comprehensive treatment based on the treatment group with naloxone HCl 0.8mg intravenously after 2.4mg +5% GS 300m l intravenous, once daily, with pulmonary or severe hypoxia The patients in control group were treated with Nicoramide 0.75-1.5 and Lobeline 9-15mg + 5% GS 500ml intravenously once daily for 5 days. The symptoms and signs were observed after treatment And 24-hour blood gas analysis. The results showed that the symptoms and signs of the treatment group improved rapidly, the patients with pulmonary brain recovery time was short, 24 hours PH, PaO2 increased significantly, PaCO2 decreased significantly, so that naloxone can be used as a new type of respiratory stimulant in clinical.